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Abstract
Objective
The study aims to describe the clinical characteristics and outcomes of patients with COVID-19 related
acute respiratory distress syndrome (ARDS) who developed pneumothorax.

Design and setting
A retrospective chart review was performed of the electronic medical record. Patients were included if they
were identified as having confirmed COVID-19 as well as pneumothorax from March 16, 2020 to May 31,
2020. Patients' demographic and clinical characteristics, mechanical ventilator parameters, lung compliance
measurements and outcomes during hospitalization were collected. This case series was conducted in
intensive care units at two large tertiary care centers within the Northwell Health System, located in New
York State.

Patients
A total of 75 patients were identified who were predominantly male (73.3%) with an average age of 62.8
years. Thirty (40%) were Hispanic, 20 (26.7%) were White, 16 (21.3%) were Asian, and nine (12%) were Black.
Common comorbid conditions were hypertension (52%), diabetes mellitus (26.7%), hyperlipidemia (32.0%),
and chronic pulmonary disease (8, 10.7%).

Measurements and main results
Most of the patients were diagnosed with pneumothorax while on mechanical ventilation (92%) despite
overall adherence with lung-protective ventilation strategies. Average tidal volume was 6.66 mL/kg) of ideal
body weight. The average positive end-expiratory pressure (PEEP) was 10.83 (cm) H2O. Lung compliance
was poor, with average peak and plateau pressures of 41.9 cm H2O and 35.2 cm H2O, respectively. Inpatient
mortality was high in these patients (76%). Conservative management with initial observation had a success
rate (73.3%) with similar mortality and shorter length of stay (LOS) on average. Significant factors in the
conservatively managed group included lack of tension physiology, the smaller size of pneumothorax, lack of
underlying diabetes, presence of pneumomediastinum, and not being on mechanical ventilation during
diagnosis.
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Conclusion
Despite overall adherence to best practice ventilator management in ARDS, we observed a large number of
pneumothoraces during the COVID-19 pandemic. Conservative management may be appropriate if there are
no clinical signs or symptoms of tension physiology and pneumothorax size is small.

Categories: Infectious Disease, Pulmonology
Keywords: covid-19, severe acute respiratory syndrome coronavirus 2, respiratory distress syndrome, pneumothorax,
lung compliance

Introduction
Coronavirus disease 2019 (COVID-19) secondary to severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) inundated the New York metropolitan area from March to May 2020. During this time period, our
health system treated over 17,000 patients with COVID-19, of which approximately 3,000 required
mechanical ventilation. While these patients presented with a wide range of illnesses, most of the intubated
patients had acute respiratory distress syndrome (ARDS).
Patients with ARDS are known to be at risk for pulmonary barotrauma during mechanical ventilation, which

How to cite this article
Wong K, Kim D, Iakovou A, et al. (November 28, 2020) Pneumothorax in COVID-19 Acute Respiratory Distress Syndrome: Case Series. Cureus
12(11): e11749. DOI 10.7759/cureus.11749

is associated with increased morbidity and mortality [1]. The mechanism involves elevated transpulmonary
pressures, alveolar rupture, and release of air into the extra-alveolar space, which can cause pneumothorax,
pneumomediastinum, and subcutaneous emphysema. The incidence of pulmonary barotrauma in
mechanically ventilated patients depends on the underlying disease process and can range from 0-50% [2].
In ARDS, the overall incidence of barotrauma is 6.5%, with a relative risk of 2.7 likely related to the low
compliance of the respiratory system in this disease state [3]. The risk of barotrauma can be reduced by
implementing lung-protective ventilation strategies [4]. Prior studies have shown that the use of high tidal
volumes and plateau pressures resulted in a 42% rate of pneumothorax and 71% mortality rate compared
with 7% and 38%, respectively, in patients in whom tidal volumes and plateau pressures were limited [5].
In the 2003 severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) epidemic, spontaneous
pneumomediastinum and pneumothorax were also reported [6]. Observational studies reported the
occurrence of pneumothorax in 20-34% of patients with SARS-CoV-1 who required mechanical ventilation
[7, 8]. There have been case reports of pneumothorax associated with COVID-19 ARDS, as well as a recently
published multicenter retrospective case series in the United Kingdom [9, 10]. Here we report the largest case
series of pneumothorax in this patient population and describe their clinical characteristics and outcomes.

Materials And Methods
Cases were collected retrospectively based on author recall. Data was collected from the electronic medical
record (EMR), Enterprise SunriseClinical Manager™ - Allscripts®, for patients with confirmed COVID-19
and pneumothorax admitted to North Shore University Hospital and Long Island Jewish Medical Center, two
large tertiary care centers within the Northwell Health System, from March 16, 2020 to May 31, 2020. The
Northwell Health System is New York State’s largest healthcare provider, consisting of a total of 23
hospitals. This case series was approved by the Northwell Institutional Review Board (IRB) as minimal-risk
research using data collected for routine clinical practice and waived the requirement for informed consent
(IRB number 20-0200).
A confirmed case of COVID-19 was defined as a positive laboratory test for SARS-CoV-2 from real-time
reverse transcription-polymerase chain reaction (RT-PCR) assay of the respiratory specimen. Pneumothorax
was identified by chest radiograph or point of care ultrasound (POCUS). The presence of tension
pneumothorax was based on documentation in the EMR as determined by the clinical team. Size of
pneumothorax was measured on upright chest radiograph when available, as the distance (mm) from lung
apex to the top margin of the visceral pleura. We collected data on patient demographics, baseline
comorbidities, invasive procedures, ventilator parameters shortly prior to pneumothorax diagnosis, length
of hospital stay prior to pneumothorax, days on mechanical ventilation prior to pneumothorax and, patient
outcomes (extubation, tracheostomy, decannulation, hospital length of stay, and in-hospital mortality).

Results
A total of 75 patients with COVID-19 and pneumothorax were identified. The average age was 62.8 years
(range: 25-90). Thirty (40%) were Hispanic, 20 (26.7%) were White, 16 (21.3%) were Asian, and nine (12%)
were Black. Patients were predominantly male (55, 73.3%). Forty-eight patients (68.6%) had a normal body
mass index (BMI 18-25), 22 (29.3%) were obese (BMI>30), and two (2.7%) were morbidly obese (BMI>40).
Comorbid conditions included hypertension (39, 52%), diabetes mellitus (20, 26.7%), hyperlipidemia (24,
32.0%), and chronic pulmonary disease (8, 10.7%). Fifteen patients (20.0%) had no past medical history
(Table 1).

Demographics

Total cohort (n=75)

Conservative* (n=15)

Invasive** (n=60)

p-value

62.8 [25 – 90]

63.67

62.13

0.682

Male

55 (73.3)

9 (60)

46 (76.7)

0.205

Female

20 (26.7)

6 (40)

14 (23.3)

0.205

Mean [Range]

28.6 [16.1 - 42.2]

27.7

28.8

0.472

Underweight

1 (1.3)

0 (0)

1 (1.7)

0.693

Normal

48 (68.6)

11 (73.3)

37 (61.7)

0.975

Obese

22 (29.3)

2 (13.3)

20 (33.3)

0.149

Morbidly obese

2 (2.7)

1 (6.7)

1 (1.7)

0.322

Age (years)
Mean [Range]
Gender

BMI (kg/m2)
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Not reported

2 (2.7)

1 (6.7)

1 (1.7)

Hispanic

30 (40)

6 (40)

24 (40)

1.000

White

20 (26.7)

5 (33.3)

15 (25)

0.528

Asian

16 (21.3)

3 (20)

13 (21.7)

0.890

Black

9 (12)

1 (6.7)

8 (13.3)

0.486

HTN

39 (52)

6 (40)

33 (55)

0.302

HLD

24 (32)

4 (26.7)

20 (33.3)

0.626

DM

20 (26.7)

1 (6.7)

19 (31.7)

0.049

COPD

8 (10.6)

0 (0)

8 (13.3)

0.138

None

15 (20)

5 (33.3)

10 (16.7)

0.153

Mild (200-300)

12 (16)

2 (13.3)

10 (16.7)

0.749

Moderate (100-200)

31 (41.3)

7 (46.7)

24 (40)

0.639

Severe (<100)

32 (42.7)

6 (40)

26 (43.3)

0.818

On paralytics

23 (30.7)

3 (20)

20 (33.3)

0.321

Procedure within 24 hours prior

32 (42.6)

6 (40)

26 (43.3)

0.818

Presence of tension

29 (38.7)

0 (0)

29 (48.3)

<0.001

On mechanical ventilation

69 (92)

11 (73.3)

58 (96.7)

0.003

Pneumomediastinum also present

27 (36)

10 (66.7)

17 (28.3)

0.006

Average PTX size (mm)

35.82

10.23

44.17

<0.001

Race

Comorbidities

P/F Ratio

Other characteristics

TABLE 1: Patients' demographic and clinical characteristics
Values are expressed as number (percentage) unless otherwise indicated.
* Close observation strategy
** Immediate chest tube placement
HTN - hypertension; HLD - hyperlipidemia; DM - diabetes mellitus; COPD - chronic obstructive pulmonary disease; PTX - pneumothorax

All pneumothoraces were diagnosed by chest radiograph, POCUS, or a combination of both. Upright chest
radiograph at time of diagnosis was available in 61 patients (81.3%). Fifty-two patients had a unilateral
pneumothorax, 31 right-sided, and 21 left-sided. Twenty-three patients had bilateral pneumothoraces. Of
these, four patients initially had unilateral involvement and subsequently developed a contralateral
pneumothorax. The average size of pneumothorax was 10.2 mm in the conservative group (close observation
strategy, no immediate chest tube placement) and 44.2 mm in the invasive group (immediate chest tube
placement). The average size of pneumothorax overall was 35.8 mm. Additionally, 27 patients (36.0%) also
had pneumomediastinum (Table 1).
Sixty patients (80%) had small-bore (< 20 French), pigtail chest tubes placed immediately after
pneumothorax diagnosis. Of these, 29 patients (48.3%) had clinical signs of tension (Table 1). Fifteen
patients (20%) were managed conservatively (close observation strategy, no immediate chest tube
placement), of which four patients (26.7%) ultimately failed, requiring chest tube placement 2.5 days on
average after diagnosis (range: 1 to 6 days). Of the four patients who failed conservative management, the
average size of pneumothorax was 18.7 mm (3 mm, 9.8mm, 15 mm, 47 mm). Indications for chest tube
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placement for those who failed observation were pneumothorax enlargement on serial chest radiographs
(two patients), worsening tachypnea (one patient), and development of severe subcutaneous emphysema
with elevated ventilator peak pressures after intubation (one patient). None of those who failed conservative
management had hemodynamic compromise prior to chest tube placement. Overall, 64 patients (85.3%)
required chest tube placement, while 11 (14.7%) did not.
Thirty-three patients (44%) had a procedure performed within 24 hours of pneumothorax identification. The
most common procedures performed were intubation (15 patients, 45.5%) and central line placement (six
patients, 18.2%). Both procedures were performed in eight patients (24.2%). Additionally, pneumothoraces
were found in two patients following cardiopulmonary resuscitation (CPR) and two after tracheostomy
(Table 2).

Clinical data

Total cohort (n=75)

Conservative* (n=15)

Invasive** (n=60)

p-value

11

15.7

0.186

7.57 [0 – 47]

4.4

8.2

0.191

6.66 (1.08)

6.80 (1.29)

6.63 (1.05)

0.569

41.86 (8.13)

44.18 (9.29)

41.4 (7.88)

0.242

35.17 (8.19)

38.0 (7.55)

34.48 (9.94)

0.204

10.83 (4.19)

10.36 (3.11)

10.93 (4.39)

0.644

Inpatient deaths

57 (76)

11 (73.3)

46 (76.7)

0.788

Extubated

4 (5.3)

2 (13.3)

2 (3.3)

0.126

Tracheostomy

15 (21.7)

1 (6.7)

14 (23.3)

0.152

Decannulated

3 (4)

0 (0)

3 (16.7)

0.667

Discharged

18 (24)

4 (26.7)

14 (23.3)

0.786

Day of hospitalization at time of pneumothorax
Mean [Range]

14.72 [0 – 63]

Days on ventilator prior to pneumothorax
Mean [Range]
Tidal volume (mL/kg of IBW)
Mean (SD)
Peak pressure (cm H2O)
Mean (SD)
Plateau pressure (cm H20)
Mean (SD)
PEEP (cm H2O)
Mean (SD)
Outcome (n,%)

TABLE 2: Patients' clinical data
*Close observation strategy
**Immediate chest tube placement
IBW - ideal body weight; PEEP - positive end-expiratory pressure

Sixty-nine patients (92%) were receiving mechanical ventilation at the time of pneumothorax identification.
The average time in the hospital was 14.7 days, and the average time on mechanical ventilation was
approximately 7.5 days prior to pneumothorax identification. The average tidal volume was 6.66 milliliters
per kilogram (mL/kg) of ideal body weight (IBW) with a range of 3.16 to 8.59 mL/kg of IBW. The average
positive end-expiratory pressure (PEEP) was 10.83 centimeters (cm) H2O ± 4.19. The average peak and
plateau pressures were 41.9 cm H2O and 35.2 cm H2O, respectively (Table 2).
Twenty-seven patients received CT of the chest in the week prior to the identification of pneumothorax. The
majority showed diffuse bilateral ground-glass and consolidative opacities, while a few showed cystic
changes and traction bronchiectasis.
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At the time of analysis, 57 patients (76%) died, and 18 patients (24%) were discharged. No patients remained
endotracheally intubated; 15 patients (21.7%) underwent a tracheostomy, of which three were later
decannulated. The average time from identification of pneumothorax to death was 9.0 days. The overall
average length of stay (LOS) for discharged patients was 48.7 days, with the conservative group average LOS
being 37.5 days, and the invasive group average LOS being 51.3 days (Table 2).

Discussion
In our COVID-19 experience, we noticed a seemingly higher incidence of pneumothorax in ARDS than
expected compared to our pre-COVID-19 experience. Here, we looked at a total of 75 cases identified based
on author recall at two large tertiary hospitals. While we are unable to extrapolate the incidence of
pneumothorax in COVID-19 ARDS based on this, we were able to obtain data from a larger section of the
Northwell Health system, which demonstrated a pneumothorax incidence of 13.72% for 1,822 COVID-19
ARDS patients. For comparison, prior to COVID-19, the overall incidence of barotrauma in ARDS was noted
to be 6.5% [3].
The majority of patients in our case series were males older than 60 years with pre-existing conditions such
as diabetes, hypertension, and obesity, all of which are associated with increased severity of illness in
COVID-19 [11]. In our series, 76% of patients who developed a pneumothorax died. In comparison, data
from across the entire Northwell Health system, from the beginning of the COVID-19 pandemic
to date, shows a 68% mortality rate for 2,468 COVID-19 ARDS patients. This increased mortality
signal suggests that the occurrence of pneumothorax may be a marker of disease severity and mortality.
Our findings are different from the recently published ERS case series, which demonstrated a 63.1% overall
survival of COVID-19 patients with pneumothorax [10]. They concluded that their data did not support
previous suggestions that the development of pneumothorax is a grave prognostic marker. This difference
may be due to different patient populations as only 63.3% of their patients required
invasive ventilatory support compared to 92% of the patients in our case series. The majority of our patients
had moderate or severe ARDS (84%) (Table 1). We were unable to compare ARDS severity as it was not
reported in their case series.
ARDS of any etiology is known to cause pathophysiologic alterations in the lungs that increase
pneumothorax risk [5]. Studies have shown that the implementation of lung-protective
strategies during mechanical ventilation leads to a significant reduction in this risk [5]. Ninety-two
percent of the patients in our case series were on mechanical ventilation at the time of pneumothorax
identification. The average tidal volume and PEEP were within the acceptable range for lung-protective
ventilation. Ventilator dyssynchrony is also known to contribute to barotrauma. In our case series, 69% of
patients were not on paralytics at the time of pneumothorax identification. It is unknown if
ventilator dyssynchrony played a significant role as the majority of patients were heavily sedated.
The average length of hospitalization prior to pneumothorax identification was 14 days, and the average
time on mechanical ventilation was approximately 7.5 days prior to pneumothorax identification. Despite
the implementation of lung-protective ventilation strategies, high average peak and plateau pressures were
observed. This suggests disease progression and increased severity with subsequently reduced lung
compliance prior to the eventual occurrence of pneumothorax.
Forty-four percent of patients had a procedure prior to pneumothorax identification, with intubation being
the most common. In our pre-COVID-19 experience at our hospitals, which are major referral centers for
acute lung injury, pneumothorax is a very rare complication of intubation. This raises the question of
whether these pneumothoraces were present prior to intubation. Additionally, six patients developed a
spontaneous pneumothorax without any positive pressure ventilation, which further supports that COVID19 itself may predispose patients to the development of pneumothorax.
Conservative management (no immediate chest tube placement) had a high success rate (73.3%) in our
study despite similar disease severity as defined by Berlin criteria for ARDS. While there was no significant
difference in mortality, the conservative group had significantly shorter average LOS for discharged patients
(37.5 days vs. 51.3 days, p=0.05). This may be explained by comparing the average time to pneumothorax
resolution in the conservative group (9.3 days) compared to the average time to chest tube removal in the
invasive group (18 days). This is likely due to hesitancy in removing chest tubes once placed, as there have
been case reports of both refractory and recurrent pneumothorax in COVID-19. Recurrent pneumothorax
was not observed after chest tube removal in our case series. While there were no chest tube
related complications, this data may support a conservative strategy of watchful waiting when appropriate.
Clinical signs of tension physiology provide a clear indication for immediate intervention, present in 29
patients (38.7%) of the invasive group compared to 0 patients (0%) of the conservative
group (p=0.001). Absent signs of tension, pneumothorax size may be able to guide clinicians in choosing a
treatment strategy. The average size of pneumothorax was 10.2 mm in the conservative group and 44.2
mm in the invasive group (p<0.001). Given the high success rate of conservative management
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and similar outcomes other than shorter average LOS, conservative management in the instance of small
pneumothorax may be appropriate. Three of the four patients who failed conservative management had
relatively large pneumothoraces (9.8 mm, 15 mm, 47 mm), supporting our findings.
Not being on mechanical ventilation at the time of pneumothorax diagnosis and lack of diabetes as
comorbidity may also support opting for a conservative approach. Those who were conservatively
managed were less likely to be on mechanical ventilation at the time of diagnosis (p=0.003) and less likely to
have underlying diabetes (p=0.049). The concurrent presence of pneumomediastinum at pneumothorax does
not seem to indicate a greater need for intervention as the conservative group was more likely to
have pneumomediastinum at pneumothorax diagnosis (p<0.001).

Limitations
At the peak of the COVID-19 pandemic in New York, the overwhelming number of patients led to the
creation of surge intensive care units (ICUs). Some of these were staffed by non-critical care physicians,
nurses, and respiratory therapists that were deployed from other areas of the health system as well as other
states. This led to variability in ventilator management and documentation in the EMR.
Several limitations are inherent as this was a retrospective chart review that was dependent on the available
documentation. It was difficult to determine ventilator dyssynchrony, adequacy of sedation, and any
ventilator parameter adjustments that were not documented. The lack of real-time data on lung
compliance and clinical context hinders identifying factors that may have led to pneumothorax
development. If available, this may have allowed for differentiation between reduced lung compliance
related to ARDS and ventilator dyssynchrony.
Obtaining imaging was up to the discretion of the clinical team. Pneumothorax diagnosis may have been
incidental, due to routine chest radiographs or POCUS, or may have been directed based on clinical
suspicion, which was unable to be determined from this retrospective review. The clinical significance of an
incidental pneumothorax is unclear. Moreover, a greater number of CT scans would have given a better
insight into changes in lung architecture and any possible correlation with pneumothorax development.
There are no established guidelines or criteria of when to pursue a conservative or an invasive approach to
managing pneumothorax, both prior to and during the COVID-19 pandemic. Consequently, the choice of
management was left solely up to the clinical team, and clinical reasoning was unable to be determined from
this retrospective review.
Our cases were also collected based on author recall at two hospitals, and as such, case-capture may not have
been complete. We were also unable to access cases for the rest of the Northwell Health system, consisting of
21 other hospitals.

Conclusions
We describe a case series of patients with COVID-19 associated ARDS who developed
pneumothorax. Despite limitations, we adhered to best practice ventilator management in ARDS but
still observed a large number of pneumothoraces during this pandemic compared to our pre-COVID-19
ARDS experience. Conservative management may be appropriate if there are no clinical signs or symptoms
of tension physiology and pneumothorax size is small.

Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study. Northwell Institutional Review
Board issued approval 20-0200. Animal subjects: All authors have confirmed that this study did not involve
animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all
authors declare the following: Payment/services info: All authors have declared that no financial support
was received from any organization for the submitted work. Financial relationships: All authors have
declared that they have no financial relationships at present or within the previous three years with any
organizations that might have an interest in the submitted work. Other relationships: All authors have
declared that there are no other relationships or activities that could appear to have influenced the
submitted work.
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